Without an efficacy edge, AstraZeneca is aiming to lure doctors away from AbbVie and Johnson & Johnson’s market-leading Imbruvica by touting a better safety prof...

Bluebird Bio's beta-thalassemia gene therapy Zynteglo has struggled to spread its wings, and a recent clinical pause certainly didn't help. But with studie...

The Supreme Court has rejected Johnson & Johnson’s appeal of a $2.11 billion verdict for women who developed ovarian cancer from the company’s talc-based product...

The globe has come to depend on Moderna’s COVID-19 vaccine, sending the biotech racing to expand its mRNA manufacturing capacity. In the next step of its effort...

Attempts to rein in prescription drug prices over the past few years haven't amounted to much, but pricing is still on the agenda for President Joe Biden. Biden “s...

The vision-threatening safety risk from Novartis’ new VEGF inhibitor Beovu just got even clearer. Friday, Novartis said it had decided to nix three Beovu trials ea...

Just a handful of days are left until patients, families, investors and Biogen executives will know the next chapter for the company’s controversial Alzhei...

BridgeBio is keeping the momentum going in 2021. After winning a nod for its rare disease med Nulibry earlier this year, the FDA has handed the company an approval f...

Sometimes finding out how patients really feel about treatment takes persistence. That's what BioCryst Pharmaceuticals learned when it started talking to patients ab...

Migraines are difficult to navigate, with patients often mapping their own routes to try to avoid the debilitating episodes and to deal with them when they arise. ...